Voxel-based MRI intensitometry reveals extent of cerebral white matter pathology in amyotrophic lateral sclerosis

Viktor Hartung1, Tino Prell1, Christian Gaser2

  • 1Hans-Berger Department of Neurology, University Hospital Jena, Jena, Germany.

Plos One
|August 19, 2014
PubMed

Insights

A new MRI analysis method, voxel-based intensitometry (VBI), detects white matter changes in amyotrophic lateral sclerosis (ALS) patients. VBI shows potential as a clinical biomarker, correlating with disease severity.

Area of Science:

  • Neuroimaging
  • Neurology
  • Biomarker Discovery

Background:

  • Amyotrophic lateral sclerosis (ALS) involves progressive motor neuron loss.
  • Existing MRI methods like diffusion tensor imaging (DTI) have limitations for routine ALS white matter assessment.
  • Traditional voxel-based morphometry (VBM) is not optimal for white matter analysis in ALS.

Purpose of the Study:

  • To introduce and evaluate a novel MRI analysis technique, voxel-based intensitometry (VBI), for detecting white matter changes in ALS.
  • To assess the correlation of VBI findings with ALS disease severity and clinical presentation.
  • To explore the potential of VBI as a translatable clinical biomarker for ALS.

Main Methods:

  • Acquisition of high-resolution T1-weighted MRI scans at 1.5 Tesla.
  • Application of voxel-based intensitometry (VBI) for group-level white matter analysis.
  • Comparison of VBI results between 30 ALS patients and 37 healthy controls.

Main Results:

  • VBI revealed widespread white matter intensity increases in ALS patients across multiple tracts, including corticospinal tracts and corpus callosum.
  • VBI findings correlated significantly with disease severity (ALSFRS-R).
  • Patterns of cerebral involvement identified by VBI differed based on disease onset (bulbar vs. limb).

Conclusions:

  • Voxel-based intensitometry (VBI) is a promising novel method for analyzing white matter changes in amyotrophic lateral sclerosis (ALS).
  • VBI demonstrates potential as a clinically translatable biomarker for ALS, offering insights into disease severity and progression.
  • The technique shows promise for routine clinical application and individual patient analysis.